The beta thalassemia testing market is expected to be worth $445.57 million in 2022 and increase at an 8.2% CAGR to reach $963.62 million by 2032.

Beta thalassemia can be defined as a blood disorder characterised by decreased haemoglobin production. Hemoglobin is an iron-containing protein found in red blood cells. Its primary purpose is to transport oxygen to body cells throughout the body.

A shortage of haemoglobin in beta thalassemia patients frequently results in a loss of oxygen in numerous regions of the body. The complexion of the patient turns pale yellow due to a lack of blood in the body, and other symptoms such as weakness and exhaustion are noticeable. Patients with beta thalassemia are at a significant risk of irregular blood clotting.

North America is expected to account for a large percentage of the global market for beta thalassemia testing. The presence of large market participants in the area, as well as strong healthcare infrastructure, is credited with driving market expansion.

The Asia Pacific beta thalassemia testing market is expected to expand rapidly over the forecast period. Increased awareness of the importance of early diagnosis, as well as an increase in the number of beta thalassemia patients, are expected to drive the market.

Beta Thalassemia Testing Market: Segmentation

Valuable information covered in the FMI’s Beta Thalassemia Testing market report has been segregated into key segments and sub-segments.

Based on technology, the beta thalassemia testing Market is segmented into the following:

  • Perinatal Testing
  • Complete Blood Count (CBC)
  • DNA Testing
  • Prenatal Testing
  • Prenatal Genetic Testing
  • Chorionic Villus sampling
  • Preimplantation

Based on end user, the in vivo imaging systems market can be segmented into following:

  • Hospitals
  • Biotechnological Laboratories
  • Diagnostic Laboratories
  • Educational research institutes
  • Pharmaceutical Industries

Know More About Report@ https://www.futuremarketinsights.com/reports/beta-thalassemia-testing-market

Beta Thalassemia Testing Market: Competition Analysis

The FMI’s study presents a comprehensive analysis of global, regional, and country-level players active in the Beta Thalassemia Testing market. Competitive information detailed in the Beta Thalassemia Testing market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Beta Thalassemia Testing market report.

Key players covered in the report include:

Genorama Ltd, HiMedia Laboratories, DiagCor Bioscience Inc Ltd, Tosoh Bioscience, Inc.